2022
DOI: 10.3390/microorganisms10091699
|View full text |Cite
|
Sign up to set email alerts
|

Antibiotic Resistance in Neisseria gonorrhoeae: Challenges in Research and Treatment

Abstract: Gonococcal infection caused by the Gram-negative bacteria Neisseria gonorrhoeae is one of the most common sexually transmitted infections (STIs) worldwide [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 49 publications
0
4
0
Order By: Relevance
“…140 Cephalosporins: Third-generation cephalosporins like ceftriaxone are the first-line treatment for gonorrhea, particularly in cases of antimicrobial resistance. 141 They are also used to treat PID in combination with other antibiotics. The updated 2020 European guidelines advise a combination of two antimicrobial therapies, which involve intramuscular injection of 1 g ceftriaxone along with a single oral dose of 2 g azithromycin, or solely 1 g ceftriaxone by intramuscular injection if laboratory testing has indicated no resistance to ceftriaxone.…”
Section: Antibiotics In the Treatment Of Reproductive Tract Infectionsmentioning
confidence: 99%
“…140 Cephalosporins: Third-generation cephalosporins like ceftriaxone are the first-line treatment for gonorrhea, particularly in cases of antimicrobial resistance. 141 They are also used to treat PID in combination with other antibiotics. The updated 2020 European guidelines advise a combination of two antimicrobial therapies, which involve intramuscular injection of 1 g ceftriaxone along with a single oral dose of 2 g azithromycin, or solely 1 g ceftriaxone by intramuscular injection if laboratory testing has indicated no resistance to ceftriaxone.…”
Section: Antibiotics In the Treatment Of Reproductive Tract Infectionsmentioning
confidence: 99%
“…The surveillance includes systematic monitoring of treatment failures and the use of molecular AMR prediction methods. The WHO recommends that gonorrhoea management guidelines should be revised based on recent and quality-assured gonococcal AMR surveillance data and that first-line empirical gonorrhoea treatment should be discontinued when the level of treatment failures and/or in vitro AMR reach 5% [32]. However, the evidence for the ≥ 5% AMR threshold is limited, and proportions of ≥ 1% and > 3% resistance in high-frequency transmitting populations has also been suggested [2].…”
Section: Who Surveillancementioning
confidence: 99%
“…N. gonorrhoeae has developed resistance to antibiotics previously recommended for firstline empirical treatment of gonorrhoea [4] . Resistance has been reported to antibiotics including ciprofloxacin, azithromycin, cefixime, and ceftriaxone [4][5][6][7][8] . Further, resistance to ceftriaxone, the last option for monotherapy, is evolving [9] .…”
Section: Introductionmentioning
confidence: 99%